News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
ESMO Advanced Course on ADC Development, Therapeutic Applications and Research
Photo from ESMO/LinkedIn
Jul 20, 2024, 10:15

ESMO Advanced Course on ADC Development, Therapeutic Applications and Research

shared a post on LinkedIn:

“ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Thoracic and GU Cancers 2024.   .

Application deadline is around the corner, don’t miss the opportunity to apply before the 23rd July 2024.

More details here.”

Source:

ADC development Advanced Course cancer ESMO European Society for Medical Oncology GU cancer OncoDaily Oncology Therapeutic Applications thoracic cancer
Special Coverage
Blog
Mar 12, 2025, 06:06
Transforming Cancer Research into Accessible Care - CancerX
Blog
Mar 12, 2025, 06:04
Fabio Ynoe de Moraes: The Tsunami of Research is Here. Are You Ready?
Blog
Mar 12, 2025, 05:56
Certificate of Advanced Studies in Prostate Cancer - European School of Oncology
Blog
Mar 12, 2025, 05:55
Gertjan Kaspers: The Neuro-oncology module of the 4th Master Course
Blog
Mar 12, 2025, 05:45
Sofiat Akinola: Why investing in diagnostics is fundamental to achieving women's health equity
Blog
Mar 12, 2025, 05:40
Over $850,000 raised for childhood cancer research at Melbourne gala event - the Autumn Ball - Children's Cancer Institute
Blog
Mar 12, 2025, 05:31
Interview with Expert: Steve Bierman
Science
Mar 11, 2025, 16:56
Ajay Major: Patient and care partner perspectives on treatment decision-making in NLPHL
Blog
Mar 11, 2025, 16:48
How to make your abstract stand out at SIOP 2025
Blog
Mar 11, 2025, 16:33
The first episode of the Diary of an Oncology Leader series - ESMO
Blog
Mar 11, 2025, 16:24
Olubukola Ayodele: Cancer care should be about healing the whole person
Oncolibrary
Mar 11, 2025, 16:02
VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer